Skip to main content
Premium Trial:

Request an Annual Quote

William Radany, Kirk Collamer, John Jaskowiak, Larry Tiffany, Peter Goodfellow

Premium
William Radany has been named CEO of HTG, the array company said this week. He replaces Kirk Collamer, who will remain with HTG as its chief financial officer.
 
Radany joins HTG from Chemicon International, an immunological reagents, immunodiagnostics, and molecular biology products provider, where he served as vice president of business segment management.
 
Prior to Chemicon International, Radany was chief business officer at Xencor. He has also served as vice president of drug discovery programs at both Caliper Technologies and Stratagene, as well as president of Biacore.
 
Radany holds a BS in cell biology from Colorado State University and a PhD in biochemistry and physiology from the University of Wyoming.
 

 
ExonHit Therapeutics has hired John Jaskowiak as executive vice president of business and marketing. Jaskowiak will work out of the Paris-based company’s US subsidiary in Gaithersburg, Md.
 
Jaskowiak comes to ExonHit from Affymetrix, where he was senior director of marketing. His goal at ExonHit will be to “develop a partnering business model for ExonHit's genomics efforts to expand ExonHit's business in diagnostics and personalized medicines," the company said in a statement.
 

 
Gene Logic has extended until Dec. 31 the employment of Larry Tiffany as senior vice president and interim general manager of its Genomics Division. The company originally signed him up for these duties on June 30 and said he would remain employed until Aug. 31.
 

 
DeCode Genetics appointed Peter Goodfellow to its board of directors, effective immediately.
 

Goodfellow was until recently senior vice president for discovery research at GlaxoSmithKline. He received his PhD from Oxford University

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.